Beyond axillary lymph node metastasis, BMI and menopausal status are prognostic determinants for triple-negative breast cancer treated by neoadjuvant chemotherapy

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Bonsang Kitzis, Hélène ^a,c   Chaltier, Léonor ^a   Belin, Lisa ^a   Savignoni, Alexia ^a   Rouzier, Roman ^a   Sablin, Marie Paule ^a   Lerebours, Florence ^a   Bidard, François Clément ^a   Cottu, Paul ^a   Sastre Garau, Xavier ^a   Laé, Marick ^a   Pierga, Jean Yves ^a,b   Reyal, Fabien ^a,c  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BODY MASS; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; METASTASIS FREE SURVIVAL; OBESITY; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; AXILLA; CARCINOMA, DUCTAL, BREAST; LYMPH NODE; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AXILLA; BODY MASS INDEX; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MENOPAUSE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84956964126     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144359     Document Type: Article

References (42)

1. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98: 262-272. doi: 10.1093/jnci/djj052
2. Sorlie T. Molecular classification of breast tumors: Toward improved diagnostics and treatments. Methods Mol Biol Clifton NJ. United States; 2007; 360: 91-114. doi: 10.1385/1-59745-165-7:91
3. Carey LA. Directed therapy of subtypes of triple-negative breast cancer. The oncologist. United States; 2011; 16 Suppl 1: 71-78. doi: 10.1634/theoncologist.2011-S1-71
4. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363: 1938-1948. doi: 10.1056/NEJMra1001389
5. Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, et al. Statement of the Science Concerning Locoregional Treatments After Preoperative Chemotherapy for Breast Cancer : A National Cancer Institute Conference. 2008; 26: 791-797. doi: 10.1200/JCO.2007.15.0326
6. Fisher CS, Ma CX, Gillanders WE, Aft RL, Eberlein TJ, Gao F, et al. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann Surg Oncol. United States; 2012; 19: 253-258. doi: 10.1245/s10434-011-1877-y
7. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2007; 25: 4414-22. doi: 10.1200/JCO.2007.10.6823
8. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia J, et al. Response to neoadjuvant therapy and long-Term survival in patients with triple-negative breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008; 26: 1275-81. doi: 10.1200/JCO.2007.14.4147
9. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-145. doi: 10.1200/JCO. 2006.09.2775
10. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005; 11: 5678-5685. doi: 10.1158/1078-0432.CCR-04-2421
11. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol Off J Am Soc Clin Oncol. 2008; 26: 778-85. doi: 10.1200/JCO.2007.15.0235
12. Pierga JY, Mouret E, Diéras V, Laurence V, Beuzeboc P, Dorval T, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer. 2000; 83: 1480-1487. doi: 10.1054/bjoc.2000.1461
13. Tutt ANJ. Triple negative tumours: A critical review. 2008; 108-118. doi: 10.1111/j.1365-2559.2007. 02889.x
14. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res. United States; 2007; 13: 4429-4434. doi: 10.1158/1078-0432.CCR-06-3045
15. Rakha E, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109: 25-32. doi: 10.1002/cncr.22381
16. Tischkowitz M, Brunet J-S, Begin LR, Huntsman DG, Cheang MCU, Akslen LA, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. England; 2007; 7: 134. doi: 10.1186/1471-2407-7-134
17. Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res Off J Am Assoc Cancer Res. 2006; 12: 1533-9. doi: 10.1158/1078-0432.CCR-05-2281
18. Fulford LG, Reis-filho JS, Ryder K, Jones C, Gillett CE, Hanby A, et al. Research article Basal-like grade III invasive ductal carcinoma of the breast : patterns of metastasis and long-Term survival. 2007; 9: 1-11. doi: 10.1186/bcr1636
19. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Time to disease recurrence in basaltype breast cancers: effects of tumor size and lymph node status. Cancer. United States; 2009; 115: 4917-4923. doi: 10.1002/cncr.24573
20. Foulkes WD, Grainge MJ, Rakha EA, Green AR, Ellis IO. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat. Netherlands; 2009; 117: 199-204. doi: 10.1007/s10549-008-0102-6
21. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer. United States; 2007; 109: 1721-1728. doi: 10.1002/cncr.22618
22. Blows FM, Driver KE, Schmidt MK, Broeks A, Van Leeuwen FE, Wesseling J, et al. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival : A Collaborative Analysis of Data for 10, 159 Cases from 12 Studies. 2010;7. doi: 10. 1371/journal.pmed.1000279
23. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, et al. Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study. 2007; 16: 439-444. doi: 10.1158/1055-9965.EPI-06-0806
24. Millikan RC, Newman B, Tse C, Moorman PG, Smith LV, Labbok MH, et al. Epidemiology of basal-like breast cancer. 2008; 109: 123-139.
25. Tang D, Xu S, Zhang Q, Zhao W. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol Northwood Lond Engl. 2012; 29: 526-33. doi: 10.1007/s12032-011-9948-2
26. Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, et al. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat. Netherlands; 2011; 130: 587-597. doi: 10.1007/s10549-011-1616-x
27. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Stefanick ML, Wactawski-Wende J, et al. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. United States; 2011; 20: 454-463. doi: 10.1158/1055-9965.EPI-10-0974
28. Bulun SE, Chen D, Moy I, Brooks DC, Zhao H. Aromatase, breast cancer and obesity: A complex interaction. Trends Endocrinol Metab TEM. United States; 2012; 23: 83-89. doi: 10.1016/j.tem.2011.10.003
29. Stephenson GD, Rose DP. Breast Cancer and Obesity: An Update. Nutr Cancer. 2003; 45: 1-16. doi: 10.1207/S15327914NC4501-1
30. Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. 2006; 279-292. doi: 10. 1677/erc.1.00729
31. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. 2007; 2386: 2381-2386. doi: 10.1002/ijc.23192
32. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966; 50: 219-244.
33. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al. Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer. 1998; 90: 1205-1211.
34. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. JNCCN J Natl Compr Cancer Netw. 2009; 7: 99-108.
35. Lyman GH. Commentary: chemotherapy dosing in obese patients with cancer-The need for evidencebased clinical practice guidelines. J Oncol Pract Am Soc Clin Oncol. United States; 2011; 7: 17-18. doi: 10.1200/JOP.2010.000200
36. Griggs JJ, Sorbero MES, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. United States; 2005; 165: 1267-1273. doi: 10.1001/archinte.165.11.1267
37. Greenman CG, Jagielski CH, Griggs JJ. Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice. Cancer. United States; 2008; 112: 2159-2165. doi: 10.1002/cncr.23416
38. Loibl S, Möller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011; 130: 477-87. doi: 10.1007/s10549-011-1715-8
39. He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: A retrospective analysis based on a tissue microarray. Med Oncol. 2012; 29: 406-410. doi: 10.1007/s12032-011-9832-0
40. Brentani MM, Franco EL, Oshima CT, Pacheco MM. Androgen, estrogen, and progesterone receptor levels in malignant and benign breast tumors: A multivariate analysis approach. Int J Cancer. 1986; 38: 637-642.
41. Rakha EA, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic Markers in Triple-Negative Breast Cancer. 2006; 2: 4-11. doi: 10.1002/cncr.22381
42. Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, et al. A meta-Analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer Oxf Engl 1990. England; 2014; 50: 277-289. doi: 10.1016/j.ejca.2013.10.004